PLA2G4C

Across TCGA pan-cancer cohorts, PLA2G4C mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PLA2G4C data layer compared with 22 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher PLA2G4C mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PLA2G4C expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

UCEC, PDAC, and CCRCC are the cancer types where PLA2G4C mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	II,III,IV	0.444	0.941	.002	32	view →
PDAC	DFS	Median	III,IV	0.977	0.413	.004	28	view →
CCRCC	OS	Median	II,III,IV	0.890	0.548	.003	26	view →
HNSC	DFS	Median	All	1.000	0.523	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PLA2G4C–UCEC (DFS)

Open the UCEC breakdown →